The Future of Tobacco Treatment in the Health Care System
Authors: Nancy A. Rigotti
Journal: Annals of Internal Medicine (2009)

Editorials7 April 2009The Future of Tobacco Treatment in the Health Care SystemNancy A. Rigotti, MDNancy A. Rigotti, MDFrom Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-7-200904070-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail We face a conundrum in our efforts to treat tobacco use and dependence, the leading preventable cause of death in the United States (1). Most smokers know they should quit, 70% say they want to quit, and 40% report having tried to do so in the past year (2, 3). Yet the large majority of these quit attempts failed to produce long-term tobacco abstinence, despite the availability of effective treatments. The reason? Most smokers trying to quit do not use these treatments (4).We could improve the impact of tobacco treatment at the population level by delivering the message to ...References1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238-45. [PMID: 15010446] CrossrefMedlineGoogle Scholar2. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:1221-6. [PMID: 19008790] MedlineGoogle Scholar3. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51:642-5. [PMID: 12186222] MedlineGoogle Scholar4. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34:102-11. [PMID: 18201639] CrossrefMedlineGoogle Scholar5. Ellerbeck EF, Mahnken JD, Cupertino AP, Cox LS, Greiner KA, Mussulman LM, et al. Effect of varying levels of disease management on smoking cessation. A randomized trial. Ann Intern Med. 2009;150:437-46. LinkGoogle Scholar6. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers. A randomized trial. Ann Intern Med. 2009;150:447-54. LinkGoogle Scholar7. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services Public Health Service; May 2008. Google Scholar8. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359:2018-24. [PMID: 18987369] CrossrefMedlineGoogle Scholar9. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009. [PMID: 19246427] Google Scholar10. Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med. 2008;148:554-6. [PMID: 18378950] LinkGoogle Scholar11. Sherman SE. A framework for tobacco control: lessons learnt from Veterans Health Administration. BMJ. 2008;336:1016-9. [PMID: 18456633] CrossrefMedlineGoogle Scholar12. Murray RL, Coleman T, Antoniak M, Stocks J, Fergus A, Britton J, et al. The effect of proactively identifying smokers and offering smoking cessation support in primary care populations: a cluster-randomized trial. Addiction. 2008;103:998-1006; discussion 1007-8. [PMID: 18422823] Google Scholar13. Curry SJ, Keller PA, Orleans CT, Fiore MC. The role of health care systems in increased tobacco cessation. Annu Rev Public Health. 2008;29:411-28. [PMID: 18173387] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.Disclosures:Consultancies: Pfizer, Sanofi-Aventis. Grants received: Nabi Biopharmaceuticals, Pfizer, Sanofi-Aventis.Corresponding Author: Nancy A. Rigotti, MD, Massachusetts General Hospital, 50 Staniford Street, Boston, MA 02114; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffect of Varying Levels of Disease Management on Smoking Cessation Edward F. Ellerbeck , Jonathan D. Mahnken , A. Paula Cupertino , Lisa Sanderson Cox , K. Allen Greiner , Laura M. Mussulman , Niaman Nazir , Theresa I. Shireman , Kenneth Resnicow , and Jasjit S. Ahluwalia Triple-Combination Pharmacotherapy for Medically Ill Smokers Michael B. Steinberg , Shelley Greenhaus , Amy C. Schmelzer , Michelle T. Bover , Jonathan Foulds , Donald R. Hoover , and Jeffrey L. Carson Metrics Cited ByEnhancing the effectiveness of smoking treatment research: conceptual bases and progressRecruiting and engaging smokers in treatment in a primary care setting: developing a chronic care model implemented through a modified electronic health recordShould All Smokers Use Combination Smoking Cessation Pharmacotherapy? Using Novel Analytic Methods to Detect Differential Treatment Effects Over 8 Weeks of PharmacotherapyOffering Population-Based Tobacco Treatment in a Healthcare SettingImplementation of the Tobacco Tactics Program in the Department of Veterans Affairs 7 April 2009Volume 150, Issue 7Page: 496-497KeywordsDrug therapyDrugsHealth careHealth care providersHealth economicsNicotineNicotine replacement therapyPrevention, policy, and public healthTreatment guidelines ePublished: 7 April 2009 Issue Published: 7 April 2009 CopyrightCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...